| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2022 | Mar 14, 2022 | CRISPR Therapeutics AG | COO | Sell | 42.5 | -3,112 | -5.66% | ✗ | $192.9K |
| Dec 3, 2021 | Dec 7, 2021 | CRISPR Therapeutics AG | COO | Sell | 40.0 | -11,185 | -33.38% | ✗ | $773.7K |
| Sep 10, 2021 | Sep 14, 2021 | CRISPR Therapeutics AG | COO | Sell | 40.0 | -4,207 | -38.07% | ✗ | $495.8K |
| Mar 23, 2021 | Mar 25, 2021 | CRISPR Therapeutics AG | COO | Sell | 2.5 | -100,000 | -98.96% | ✓ | $12.8M |
| Mar 10, 2021 | Mar 12, 2021 | CRISPR Therapeutics AG | COO | Sell | 40.0 | -2,141 | -14.09% | ✗ | $265.8K |
| Jan 15, 2021 | Jan 20, 2021 | CRISPR Therapeutics AG | COO | Sell | 26.3 | -25,000 | -7.16% | ✓ | $5.4M |
| Jan 2, 2021 | Jan 4, 2021 | CRISPR Therapeutics AG | COO | Sell | 37.5 | -9,392 | -46.96% | ✗ | $1.4M |
| Jun 24, 2020 | Jun 26, 2020 | CRISPR Therapeutics AG | COO | Sell | 8.8 | -70,000 | -22.85% | ✓ | $5.3M |
| May 11, 2020 | May 13, 2020 | CRISPR Therapeutics AG | COO | Sell | 5.0 | -25,000 | -55.56% | ✓ | $1.5M |
| Jul 10, 2019 | Jul 12, 2019 | CRISPR Therapeutics AG | Chief Business Officer | Sell | 5.0 | -20,000 | -33.33% | ✓ | $1M |